The results showed that TXL combined with Ato inhibited serum lipid levels and aortic endothelial injury biomarkers in the COPD + AS group mice, reduced the expression of systemic inflammatory biomarkers, and inhibited the formation of atherosclerotic plaques better than Ato or TXL alone. This evidence concerns the gene TXNL1 and chronic obstructive pulmonary disease.